How Pharma Organizations Can Scale AI Agents and Stay Audit-Ready
Four principles for getting AI agents past the pilot phase in regulated pharma manufacturing.
AI agents are the latest technology that organizations are adopting at enterprise scale after finding benefits from their initial experiments. In McKinsey’s 2026 State of AI survey, 40% of respondents at large organizations reported scaling AI agents, up from 27% a year earlier. That still leaves most organizations working out how to get agents past the pilot phase. An agent that performs well in a contained test often struggles once it meets enterprise data that is scattered across team environments or governed inconsistently.
In the pharmaceutical industry, the technology needs to be even more airtight. Agents are starting to take on regulated work such as batch release recommendations and deviation analysis, where every action has to be explainable, attributable, and auditable. A shaky data foundation or a gap in governance that might slow a pilot in another industry can derail GxP compliance entirely.
Getting agents into production in this environment starts with the outcomes that have always defined pharma manufacturing: quality, reliable supply, cycle time, and compliance. Those outcomes then frame the rest of the work, from building the right foundation to governing agents the same way the organization governs its people. There are four main principles that can help pharma leaders deploy AI agents and pass the pilot phase.
Keep intelligence within governed data boundaries
As teams experiment with AI, it’s easy for each to build its own working environment, drawing data from whichever sources it can reach and using whichever models or tools are available. Each effort may solve a local problem, but together, they create disconnected pockets of intelligence operating under different rules. The organization can lose sight of who is accessing what data, how it’s being interpreted, which decisions it informs, and what actions follow. In pharma, where those decisions can affect product quality and GxP compliance, that loss of visibility is a real exposure.
The objective is to bring those workflows within clearly defined and governed boundaries. Every dataset and agent can stay where it lives, as long as the organization has consistent control over who and what can access data, how it can be processed, and which decisions and actions an agent is authorized to support or carry out. Those controls have to follow the workflow across systems, with clear ownership and a traceable record of what happened. Existing platform controls are a foundation, but each new workflow still needs its own validation, from data access through decision and action, before it supports regulated decisions.
One of the simplest ways to think about this is for an organization to consider the rules it applies to an employee, including access rights, accountability, and monitoring, and apply the same rules to every agent it deploys. A good test is to ask what a human being in a similar role would have access to. An agent building a set of quality analytics should have no more access than a human analyst doing the same job.
Make sure there are enough fingerprints, security postures, observability audits, tracing, and logging for the agent, as there would be for any human. Tomorrow’s workforce will be a combination of people and agents, so it’s important for organizations to think of these agents as part of their workforce instead of just an added tool or tacked-on technology.
The holistic view of AI
The same workforce mindset applies to the system as a whole. Organizations should think of AI and agents as supported by an operating system, a framework that gives a pool of agents a defined structure to work within. That framework can be used to set out layers for the AI, with specific actions and information residing at each one.
A governance layer sets the rules. A model layer supplies inference, whether from a frontier model maker, an open-weight model, or a small language model the company developed itself. Another layer gives data its semantic meaning. Agents cannot reliably orchestrate enterprise workflows if the underlying data, business definitions, and decision rules are inconsistent across systems. Common meaning and governance are prerequisites for agents to operate reliably at scale. A substrate layer covers the infrastructure, data access rights, and production foundation, with applications on top. Thinking in layers gives leaders a shared language for what needs to happen at each level.
The structure of the layers works across any industry. Specifics come from the choices made within each layer. Data access that is acceptable in one industry may be off-limits in another, and a pharma manufacturer’s applications and analytics will look very different from a retailer’s. Thinking about agents in this framework lets each organization decide how to put this combination of Legos together to build its own operating system. A layered approach also holds up as technology changes because if one layer becomes obsolete, the others keep working.
Keeping a human at the helm
The next question that organizations usually ask when implementing AI agents, especially in regulated environments, is how to establish a human review process and when to include a human in decision-making. But the stronger way to think about that is that a human should always be at the helm. From the beginning. The mindset should be that people always keep ownership of how work gets done, and agents multiply their productivity.
Pharma quality teams already have a model for this. Quality assurance and quality control routinely work in an arrangement where this is a maker and a checker, where one person enters and verifies data, and another confirms it is good to go. The same pattern can apply when agents take on part of the work, with fingerprinting that records whose decision each step was.
To that end, human involvement should start at design. Early on, people may review agent outputs directly, and as evidence of reliable performance grows, review can shift to exceptions for lower-risk steps, while regulated decisions keep a human sign-off. Each time a model or workflow changes, someone needs to confirm that the evals still work, that the agents have the right data and controls, and that a person remains at the decision-making table.
Define the problem before choosing a partner
At the end of all these principles is the decision to select a technology partner. Whether that be for tools or services, the first step should be defining a clear problem statement. Many pharma organizations go looking for a partner before defining what they actually want from AI; they just know they need to use it.
Think through questions such as “Which workflow is changing? How does it work today? Is AI being bolted onto the existing process, or is the process being reimagined? How does this effort work in concert with similar initiatives elsewhere in the organization?” A good partner can help sharpen those answers.
Then, look for three qualities in a tools or services partner. Find a partner who is flexible and keen on experimentation, has the discipline to move from prototype to proof of value, and has the ability to reach enterprise-grade production. That last quality is often where many organizations stumble, even when the first two qualities are there. But when programs can’t scale, they end up scrapped, rebuilt, or stuck in silos. Ensuring a technology partner can follow through on the end result is important for the longevity of any project.
Agent capabilities will keep advancing. Who knows what they’ll be able to do six months or 12 months from now? Agents may soon read across an organization’s documents and discover enterprise context on their own, and parts of today’s approach will need to adapt.
The fundamentals of the business, though, will stay the same. In pharma, the goal to manufacture drugs safely and efficiently won’t change. That foundation will always drive the decisions being made, even if entire workflows are being reimagined around AI. As long as organizations keep those fundamentals in mind and apply changes in layers, they’ll be prepared for whatever comes next.
Related to this article








